Drug intelligence / Profile preview

SIM0660

Development stage: Preclinical
Lead developer: Simcere Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIM0660 is an investigational anti-tumor therapeutic being developed by Simcere Pharmaceutical (Jiangsu Xiansheng Re Ming Pharmaceutical). It is designed to target the Vascular Endothelial Growth Factor (VEGF) signaling pathway, with pipeline documentation specifically noting activity against c-VEGF and VEGF. By inhibiting these growth factors, SIM0660 aims to suppress tumor-induced angiogenesis and lymphangiogenesis, thereby depriving the tumor of necessary nutrients and oxygen while potentially reducing metastatic spread. It is currently positioned within Simcere's oncology pipeline for the treatment of various cancers.

Other names: c-VEGF/VEGF inhibitor

Targets

VEGFA (Vascular endothelial growth factor A)VEGFC (VEGF-C)

Beyond the preview

Go deeper on SIM0660.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0660.

Explore the full profile